Regeneron Q2 2026: Revenue Surges 17% to $4.29B on Record Dupixent, Sanofi Balance Repaid, New $3B Buyback
REGN sits 34% above its 52-week low of $541.
Summary
Regeneron crushed Q2 2026 estimates with $4.29B in revenue (up 17% YoY) and non-GAAP EPS of $14.29, driven by record Dupixent sales. The Sanofi development balance is fully repaid, unlocking an additional ~$250M in quarterly profit sharing. A new $3B buyback was authorized, and the FDA approved gene therapy Otarmeni.
Key Events · Earnings and Guidance · REGN
-
Q2 Revenue and EPS Blowout
Revenue of $4.29B (+17% YoY) and non-GAAP EPS of $14.29 beat consensus by 12% and nearly 40%, respectively, fueled by Dupixent global sales of $5.998B (+38% YoY).
-
Sanofi Development Balance Fully Repaid
The Sanofi development balance was fully repaid as of June 30, 2026, meaning the $253M quarterly reimbursement that reduced collaboration revenue will cease starting Q3 2026, directly boosting Regeneron's share of profits.
-
New $3B Share Repurchase Program
Board authorized a new $3.0 billion share repurchase program in April 2026; $2.534B remained available as of June 30. Combined with the quarterly $0.94 dividend, capital returns are accelerating.
-
Pipeline: FDA Approves Otarmeni, Fianlimab Phase 3 Miss
FDA approved gene therapy Otarmeni for hearing loss; Lynozyfic showed 100% hematologic complete response in amyloidosis. However, fianlimab + Libtayo missed its primary endpoint in first-line metastatic melanoma vs. pembrolizumab.
Analysis · REGN · Life Sciences
A massive Q2 beat saw revenue climb 17% year-over-year to $4.29 billion, powered by Dupixent global sales soaring 38% to nearly $6 billion. Non-GAAP EPS of $14.29 crushed consensus by almost 40%. With the Sanofi development balance now fully repaid, an additional $253 million in quarterly profit sharing will flow directly to Regeneron starting in Q3. The company also authorized a new $3 billion share repurchase program and disclosed U.S. government pricing agreements that lock in Most-Favored-Nation pricing while exempting Regeneron from Section 232 tariffs through 2029. On the pipeline front, the FDA approved the gene therapy Otarmeni, though fianlimab missed its Phase 3 primary endpoint in first-line melanoma. Multiple legal proceedings advanced, including a favorable ruling that dismissed most of Amgen's counterclaims in the EYLEA biosimilar litigation. A temporary manufacturing interruption in Limerick, Ireland pressured gross margins to 78% from 83% a year ago, but production has since normalized. The quarter underscores Dupixent's dominance and Regeneron's ability to convert top-line growth into shareholder returns, even as EYLEA franchise erosion and pipeline setbacks warrant monitoring.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.8% of the 328 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $724.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.